Xeris Biopharma Holdings, Inc. Share Price
XERSXeris Biopharma Holdings, Inc. Stock Performance
Open $6.04 | Prev. Close $6.01 | Circuit Range N/A |
Day Range $5.91 - $6.07 | Year Range $3.81 - $10.07 | Volume 9,826 |
Average Traded $6.00 |
Xeris Biopharma Holdings, Inc. Share Price Chart
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
08-Apr-26 | $6.18 | $5.93 | +0.85% |
07-Apr-26 | $5.97 | $5.88 | -2.81% |
06-Apr-26 | $6.06 | $6.05 | +0.17% |
02-Apr-26 | $5.93 | $6.04 | +0.08% |
01-Apr-26 | $5.88 | $6.04 | +4.14% |
31-Mar-26 | $5.72 | $5.79 | +3.39% |
30-Mar-26 | $5.33 | $5.61 | +3.60% |